Month: March 2023

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine PipelineTen presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM) AC Immune’s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer’s diseaseLausanne, Switzerland, March 20, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that ten presentations will be delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM 2023), taking place in Gothenburg, Sweden, and virtually, on March 28 – April 1, 2023. In addition, Johannes Streffer, M.D., Chief Medical Officer of AC Immune, will join an expert panel to discuss the latest...

EXA TAE Network Map https://exainfra.net/tae-trans-adriatic-express/SAN JOSE, Calif., March 20, 2023 (GLOBE NEWSWIRE) — Infinera (NASDAQ: INFN) announced today that EXA Infrastructure (EXA) has deployed Infinera’s ICE6 800G coherent optical solution on the EXA Trans Adriatic Express (TAE), a submarine cable system linking EXA’s current European footprint to Turkey via Albania and Greece. TAE is a joint venture formed between EXA and Trans Adriatic Pipeline Ag (TAP), the owner of a critical new gas pipeline connecting the Caspian Sea to southern Italy. Completed in 2020, the pipeline connects Melendugno in southern Italy through Albania and Greece to the Turkish border at Kipoi. This project creates a unique fiber optic network connecting Milan, Tirana, Athens, Sofia, and Istanbul with high-quality, high-performance, and ultra-reliable...

Nes-Ziona, Israel, March 20, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that an independent Data and Safety Monitoring Board (DSMB) has completed an interim data review for the first cohort of patients in the Company’s ongoing Phase I/II clinical trial of Allocetra™ in patients with advanced-stage peritoneal metastasis arising from solid tumors as an add-on to the standard of care (SoC) chemotherapy administered via Pressurized Intraperitoneal Aerosol Chemotherapy (clinicaltrials.gov Identifier: NCT05431907). The Israeli Ministry of Health (IMOH) also reviewed the interim data and provided regulatory clearance to continue the study and open the study’s next cohort. In addition, the safety profile supported...

Amended Credit Facility to Focus on Retail and Institutional Investor Awareness ARLINGTON, Va., March 20, 2023 (GLOBE NEWSWIRE) — Edge Total Intelligence Inc. (TSXV: CTRL, OTCQB: UNFYF, FSE: Q5i)(“edgeTI”, “We”, “Our” or the “Company”), announces that it has amended its line of credit facility (the “Credit Facility”) with Lotus Domaine III LP (“Lotus”), an investment fund which is also a significant shareholder of the Company. “This amendment increases our line of credit and adds the Company’s election to convert this debt into common shares, which when executed will improve our debt ratio and other related metrics as we look to reach cash-flow positive operations”, remarked Jim Barrett, CEO of edgeTI. “The increase intends to better support existing and new investors and prepare edgeTI for growth as we help customers...

Figure 1: Stress levels in treated rats (as indicated by self-harm) An indicator of stress in laboratory rats is a propensity for self-harm. The stress level of the rats was found to be correlated with functional recovery, i.e. recovered rats did not exhibit self-harm.TORONTO and TEL AVIV, Israel, March 20, 2023 (GLOBE NEWSWIRE) — Toronto and Tel Aviv, March 20, 2023 – Biopharmaceutical firm NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”), disclosed today additional results from an internal preclinical study of its investigational drug ExoPTEN demonstrating effective treatment of 75% of paralyzed rats suffering from spinal cord injuries. The Company’s most recent preclinical trials, that have taken place over 10 weeks in NurExone’s labs in Israel, have proven that its experimental drug...

Represents Societal CDMO’s First Commercially Manufactured Tablet Product, Expanding Beyond Expertise in Commercial Capsules SAN DIEGO, Calif. and GAINESVILLE, Ga., March 20, 2023 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the United States Food and Drug Administration (FDA) has approved the company as a manufacturer of a commercial tablet product. Societal CDMO expects to begin commercial manufacturing of the product at its Gainesville, Georgia facilities later this year. “This FDA approval, which represents the first commercial tablet that Societal CDMO has been approved to manufacture,...

HOUSTON, March 20, 2023 (GLOBE NEWSWIRE) — Amplify Energy Corp. (“Amplify” or the “Company”) (NYSE: AMPY) today announced that Dan Furbee has joined the Company as Senior Vice President and Chief Operating Officer. “I am excited to announce that Dan has decided to join Amplify. Dan will be a valuable addition to the management team and brings extensive operational and managerial experience to the Company that will help maximize the value of our cash flow generating properties,” said Martyn Willsher, President and Chief Executive Officer. Prior to joining Amplify, Mr. Furbee served as a partner at Sentinel Petroleum from February 2022 to March 2023 and as an independent advisor for various companies from January 2021 to January 2022. Previously, Mr. Furbee served as the Executive Vice President and Chief Operating Officer of Riviera...

– Positive neuroprotective effect of vorolanib, the active drug in EYP-1901, in a widely validated retinal detachment model demonstrates a potential new mechanism of action for the treatment of retinal disease – – Clinical outcomes from real-world CALM registry study of YUTIQ® demonstrates effective control of inflammation in chronic posterior segment uveitis – WATERTOWN, Mass., March 20, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced multiple scientific presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held April 23 – 27 in New Orleans, Louisiana. “We are excited to be presenting these...